Twenty-six patients with hematologic disorders developed 27 episodes of bacteremia with S . aureus (10 with MRSA and 17 with MSSA) ( Table 2 ). One patient with acute leukemia had two episodes of MRSA bacteremia separated by six months. For ease of presentation , therefore, the terms episodes and patients will be used interchangeably. Patients with MRSA bacteremia were younger on average than those with MSSA bacteremia, with no statistically significant difference . Male preponderancewas seen in both Table 3 Comparison of MRSA and MSSA bacteremias *1 The two patients with pneumonia and extremity celiulitis were transterrea atter at least a two-weeK stay al alloulel hospital. *2 The metastatic lesions were seen alone or in combination . *3 At autopsy microabscesses were evenly distributed in the brain, thyroid, lungs, heart, pancreas and kidneys. *4In one patient who had two discrete episodes of bacteremia due to the same MRSA, only the first episode was considered. *5 Three patients , including one with MRSA bacteremia, had skin infections prior to onset of bacteremia, while the other one had no known source for the blood isolate. *6 Only monomicrobial episodes were considered . *7 All three patients had a refractory hematologic malignancy at the time of their death from shock.
Abbreviations:
PIPC, piperacillin; GM, gentamicin; NTL, netilmicin; CMZ, cefinetazole; CZX, ceftizoxime; SBPC, sulbenicillin; TOB, tobramycin; CPZ, cefoperazone; IPM/CS, imipenem/cilastatin; and ABPC, ampicillin. patient groups. Twenty-four patients (92%) had hematologic malignancies and received antineoplastic therapy prior to the onset of bacteremia. Acute leukemia and malignant lymphoma were the two most common underlying diseases. On the other hand, the remaining two patients who developed MRSA bacteremia had severe aplastic anemia and refractory idiopathic thrombocytopenic purpura complicated by cerebral hemorrhage.
Comparison of MRSA and MSSA bacteremias The clinical features of MRSA and MSSA bacteremias are shown in Table 3 . Clinical background: Bacteremia with S. aureus was in most cases hospital-acquired and monomicrobial (23 and 22 of all 27 episodes, respectively). It occurred mostly in association with neutropenia and to a lesser extent with hypoproteinemia and/or hypoalbuminemia (22 and 12 episodes, respectively) .
All of 10 patients with MRSA bacteremia had been given antibiotic therapy , including a Plactam antibiotic, in the preceding two weeks compared with five (29%) of 17 with MSSA bacteremia (p<0 .001). Piperacillin combined with an aminoglycoside had most often been used (six with MRSA bacteremia and four with MSSA bacteremia). On the other hand, MRSA bacteremia occurred more frequently after more than one month of hospitalization (eight of 10 episodes) than MSSA bacteremia (seven of 17) . However, the difference was not statistically significant (p=0.10).
Primary and secondary foci: The infectious process did not seem to differ materially between MRSA and MSSA bacteremias. The primary focus was identified in all but two episodes (25 of 27 , 93%). The most common source was the skin (boils and cellulitis), followed in order of frequency by the upper respiratory tract (pharyngitis, tonsillitis and sinusitis), and an infected central venous catheter and pneumonia . On the other hand, metastasis occurred in five of 10 patients with MRSA bacteremia and three of 17 with MSSA bacteremia, with no statistically significant difference . The most common secondary focus was the lung (lung abscesses and/or pneumonia), followed by the skin (septicemids) and microabscesses in multiple organs. Autopsy was performed on seven patients, including four with secondary septic lesions . No case of clinically-evident or autopsy-proven endocarditis was found in this series .
Surveillance cultures: In 22 patients (85%) with S. aureus bacteremia , surveillance cultures grew an identical organism at or prior to the onset . MRSA was mostly acquired during hospitalization (six of eight patients with positive cultures), whereas MSSA was often detected in admission cultures (11 of 14) . Among the other four patients with consistently negative throat cultures, skin infections were found in three , with no obvious source in the remaining one . On the other hand, surveillance cultures of the stool and urine were consistently negative in all patients with S. aureus bacteremia .
Duration of survival: Overall one and four-week survival was observed in 19 (86%) and 15 (68%) , respectively, of 22 patients with monomicrobial bacteremia , regardless of whether the causative organisms were MRSA or MSSA. The duration of survival did not significantly correlate with the neutrophil count at onset or with its increase during therapy. All three patients who died within a week of onset had a refractory hematologic malignancy.
Development of shock: Septic shock developed in seven (32%) of 22 patients with monomicrobial bacteremia, irrespective of whether the causative organisms were MRSA or MSSA . The frequency of shock was not significantly related to the neutrophil count at onset. Antibiotic treatment: Among 22 patients with monomicrobial bacteremia, only one with MRSA bacteremia died before receiving adequate therapy. The other eight patients with MRSA bacteremia were treated mostly with various combinations of in vitro effective antibiotics , such as vancomycin, cefmetazole, fosfomycin, minocycline and aminoglycosides. Seven of them survived longer than one week , including all four who received vancomycin as a major antistaphylococcal drug, and three who were treated with fosfomycin plus imipenem/cilastatin, minocycline plus netilmicin, and minocycline plus cefmetazole plus tobramycin, respectively. On the other hand, 12 of 13 patients with MSSA who received combination therapy including cefmetazole or cefazolin survived longer than one week.
Discussion
Among the blood isolates obtained from our patients with acute leukemia during the 20-year period, 1972-1991, gram-positive cocci, including S. aureus, have emerged as important pathogens since the early 1980s7). This seemed to coincide principally with the common use of second-and third-generation cephems and central venous catheters9). However, the frequency of S. aureus increased only slightly from 2% in the first decade to 5% in the latter decade, although MRSA virtually replaced MSSA inthe last five years7). On the other hand, in Europe and the United States, S. aureus continues to be one ofthe five most common blood isolates from neutropenic cancer patients, mostly those with acute leukemia, with the frequency ranging from 9% to 17% of all isolates3)-6). In contrast to the widespread use ofsemisynthetic penicillinasestable penicillins in these countries, we have often used cefazolin and cefmetazole for the treatment of staphylococcal infections as well as for the empiric treatment of febrile neutropenic patients with cancer. The former first-generation cephem has most potent activity against MSSA, whereasthe latter secondgeneration cephem is known to have some affinity for penicillin-binding protein 2' produced by MRSA13), which plays a major role in exhibiting resistance to most penicillins and cephems14). The discrepancy in the frequency of S. aureus, therefore, may partly reflect the regional difference in the type of commonly used j3-lactam antibiotics. This may be why the nationwide spread of MRSA in Japan wasdelayed a few years compared with western countries.
Both types of S. aureus bacteremia were most likely to occur in close association with neutropenia. Pharyngeal colonization often preceded the development of bacteremia. Antibiotic therapy during the hospital stay predisposed to pharyngeal colonization with MRSA which shows resistance to most of the commonly used antibiotics, whereas most blood isolates of MSSA were detected in throat cultures taken on admission. This is probably why MRSA bacteremia, as reported by Crossley et al. 15 ) and Myers et al. 16 ), tended to occur later in hospitalization compared with MSSA bacteremia.
There was no case of clinically-evident or autopsy-proven endocarditis found in our small series of patients with S. aureus bacteremia. This is consistent with the observations of Sotman et al. 17 ) and Espersen et al.18) , who advocated a shorter duration of antibiotic therapy. However, much attention should be devoted to the fact that secondary foci were found in 30% of our patients, although Sotman et al.17) reported that no such lesions were observed in their series. Considering such a high risk of metastatic infections other than endocarditis, therefore, prolonged antibiotic therapy seemswarranted in neutropenic patients, particularly those who have evident secondary septic lesions. Patients with MRSA bacteremia have been reported to have a poorer clinical prognosis than those with MSSA bacteremia1, 12, 16, 19) . Indeed, debilitated inpatients with severe underlyingdiseases are most likely to develop bacteremia due to MRSA, which is often acquired through antibiotic administration. From this standpoint, reducing the acquisition of MRSA from the hospital environment is most urgent for infection prevention. When patients belonging to almost the same disease category were compared in this study, however, the difference in survival between the two patient groups did not reach significance. This was also indicated by the study of Shimada et al.1) carried out in aged patients. Theprognosis of S. aureus bacteremia, therefore, seems to depend largely on host factors, such as severity of underlying disease and undernutrition.
In the series of Craven et al.20) , as suggested from our study, the survival rate for MRSA bacteremia treated with vancomycin was similar to that for MSSA bacteremia treated with a penicillinase-stable penicillin or a cephem. In parallel with the use of vancomycin, therefore, the distinction between MRSA 
